New publication describes effective reversal of Pradaxa in healthy volunteers
Posted: 16 June 2015 |
Results from a healthy volunteer study investigating the reversal of the anticoagulant effect of Pradaxa by idarucizumab have been published…
Results from a healthy volunteer study investigating the reversal of the anticoagulant effect of Pradaxa® (dabigatran etexilate) by its specific reversal agent idarucizumab have been published.
The study showed that idarucizumab led to immediate, complete and sustained reversal of the anticoagulant effect of Pradaxa. The data support the specific reversal agent as a highly targeted treatment option if reversal of the anticoagulant effect is needed, e.g. for urgent interventions. Idarucizumab was granted Breakthrough Therapy Designation by the US FDA and has recently been submitted for approval to the FDA, EMA and Health Canada.
Anticoagulation was reversed back to baseline levels after infusion of ifarucizumab
In the healthy volunteer study, participants first received Pradaxa and then idarucizumab. The specific reversal agent was given two hours after the last dose of Pradaxa, when dabigatran concentrations were at peak levels. After a five-minute infusion of idarucizumab, anticoagulation was immediately reversed back to baseline levels. The reversal effect was sustained for more than 24 hours for all doses of 2g and above. Idarucizumab was well tolerated by the study participants.
“The data now published in The Lancet show in an impressive manner how effective idarucizumab was for reversing Pradaxa in healthy volunteers”, said Professor Jörg Kreuzer, Vice President Medicine Therapeutic Area Cardiovascular, Boehringer Ingelheim. “Once approved, the availability of a specific reversal agent for a NOAC will be yet another landmark in anticoagulation care.”
Similar results were also seen in elderly and renally impaired volunteers in a study presented at the Annual Meeting & Exposition of the American Society for Hematology in December 2014. Boehringer Ingelheim is now evaluating idarucizumab in the RE-VERSE AD study, the first study to investigate a reversal agent to a non-vitamin K antagonist oral anticoagulant in patients.